Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 21 of 25

COMPLETED Phase 2

Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia

NCT00567671

COMPLETED Phase 4

Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery

NCT00596687

COMPLETED Phase 4

Basal Insulin in the Management of Patients With Diabetic Ketoacidosis (DKA)

NCT00590044

TERMINATED

Examining Developmental Changes in Heart Contractions of Children With Congenital Heart Defects

NCT00860327

COMPLETED

Heart Failure Study: The Atlanta Cardiomyopathy Consortium

NCT00599014

COMPLETED Early Phase 1

Evaluation of BOTOX® With Rehabilitation Therapy for the Treatment of Wrist and Hand Spasticity in Post-Stroke Patients

NCT00565201

COMPLETED

Evaluating the Effects of Stress in Pregnancy

NCT00525226

COMPLETED NA

Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study

NCT00674336

COMPLETED Phase 1

Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2

NCT00400374

TERMINATED

Adult Pulmonary Valve Replacement: A Simple and Reproducible Technique

NCT00384163

COMPLETED Phase 4

IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures

NCT00510783

COMPLETED NA

Evaluation of Atorvastatin on Atherosclerosis Composition

NCT00576576

COMPLETED

TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients

NCT00604669

COMPLETED NA

The Effect of Supplemental Docosahexaenoic Acid (DHA) on Neurocognitive Outcomes in Teen and Adult Women With Phenylketonuria(PKU)

NCT00892554

COMPLETED NA

Modified Perfusion for Neonatal Aortic Arch Reconstruction

NCT00490256

TERMINATED Phase 4

Clinical Effects of Vitamin D Repletion in Patients With Parkinson's Disease

NCT00571285

COMPLETED

Ketosis Prone Diabetes in African-Americans

NCT00426413

TERMINATED Phase 1

Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

NCT00472082

COMPLETED

SPY Imaging System: Its Role in Pediatric Cardiac Surgery

NCT00446927

COMPLETED Phase 1

Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)

NCT00967096

COMPLETED NA

Neurobiological Principles Applied to the Rehabilitation of Stroke Patients

NCT00715520

COMPLETED

Speckle Tracking in Pediatric Patients

NCT00489957

COMPLETED

Virtual Reality Helmet to Test for Problems With Memory

NCT00454454

TERMINATED Phase 4

BNP Therapy Observation Unit Outcomes STudy (BOOST)

NCT00453453

TERMINATED NA

Intraosseous Infusion of Unrelated Cord Blood Grafts

NCT00967525

COMPLETED NA

Acupuncture for Pain and Sleep Disturbance in Knee Osteoarthritis

NCT00694447

COMPLETED

Retrospective Pulmonary Valve Replacement Imaging

NCT00446108

COMPLETED

Champy Versus AO for Mandible Fractures

NCT00628849

COMPLETED Phase 2

Family-Focused, Stress-Reduction Program to Improve the Health Care of Urban Children With Asthma

NCT00384813

COMPLETED NA

SMART Trial Longitudinal Follow-Up:Off-Pump Versus On-Pump Coronary Artery Bypass Surgery

NCT00209053

COMPLETED NA

A Comparison of Arthrocentesis, Arthroscopy and Arthroplasty in the Treatment of Temporomandibular Joint Dysfunction

NCT00636727

COMPLETED Phase 2

Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation

NCT00548847

COMPLETED

Exercise in Chronically Paced Children

NCT00374608

COMPLETED

Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve

NCT00412386

COMPLETED Phase 1

Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

NCT00972712

COMPLETED Phase 4

Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes

NCT00590226

COMPLETED

Follow Up on Freestyle Valves in Children

NCT00385112

COMPLETED

Neurodevelopmental Outcomes in Hypoplastic Left Heart Syndrome

NCT00399555

COMPLETED Phase 2

Topical 0.4% Ketorolac and Vitreoretinal Surgery

NCT00576329

COMPLETED

Protective Immunity Project 02

NCT00833651

COMPLETED Phase 1

Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT00401778

TERMINATED Phase 1

Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer

NCT00406276

COMPLETED Phase 4

Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

NCT00352885

COMPLETED Phase 1

Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor

NCT00314262

COMPLETED Phase 3

Efficacy and Mechanisms of GLN Dipeptide in the SICU

NCT00248638

COMPLETED

Protective Immunity Project 01

NCT00788021

COMPLETED NA

Medical Self-Management for Improving Health Behavior Among Individuals in Community Mental Health Settings

NCT00380536

COMPLETED

Acoustic Startle Reduction In Cocaine Dependence

NCT00430690

COMPLETED Phase 2

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

NCT00356278

TERMINATED Phase 2

Vitamin B12 Status and Response to Vitamin B12 Supplementation in Patients With Parkinson's Disease

NCT00208611

← Previous Page 21 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.